Bone Biologics (BBLG) Net Cash Flow (2013 - 2025)
Bone Biologics (BBLG) posted quarterly Net Cash Flow of -$723612.0 for Q4 2025, down 199.89% year-over-year from $724431.6 in Q4 2024, and down 22.36% quarter-over-quarter from -$591384.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Net Cash Flow (2013 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Net Cash Flow for 14 consecutive years, with -$723612.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 199.89% year-over-year to -$723612.0; the TTM figure through Dec 2025 stood at $2.0 million (up 569.99% YoY), while the FY2025 annual figure was $2.0 million, up 569.99% from the prior year.
- Net Cash Flow eased to -$723612.0 in Q4 2025 per BBLG's latest filing, from -$591384.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $6.7 million in Q4 2021 and bottomed at -$3.6 million in Q2 2023.
- Historically, Net Cash Flow has averaged -$177827.6 across 5 years, with a median of -$486927.5 in 2022.
- Annual changes were most pronounced in 2021 — Net Cash Flow jumped 271208.94% — and 2022, when it plunged 37050.28%.
- Bone Biologics' Net Cash Flow stood at $6.7 million in 2021, then sank by 129.24% to -$2.0 million in 2022, then gained by 26.9% to -$1.4 million in 2023, then surged by 83.08% to -$241295.0 in 2024, then plunged by 199.89% to -$723612.0 in 2025.
- Business Quant data shows BBLG's Net Cash Flow at -$723612.0 in Q4 2025, -$591384.0 in Q3 2025, and $3.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -700,000.00 |
| Sep 30, 2025 | -614,996.00 |
| Jun 30, 2025 | 3.89 Mn |
| Mar 31, 2025 | -578,576.00 |
| Dec 31, 2024 | -241,295.00 |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | -895,566.00 |
| Mar 31, 2024 | 201,065.00 |
| Dec 31, 2023 | -1.43 Mn |
| Sep 30, 2023 | -2.56 Mn |
| Jun 30, 2023 | -3.63 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.95 Mn |
| Sep 30, 2022 | -395,279.00 |
| Jun 30, 2022 | -360,064.00 |
| Mar 31, 2022 | -860,779.00 |
| Dec 31, 2021 | 6.67 Mn |
| Sep 30, 2021 | -1,064.00 |
| Jun 30, 2021 | -66,727.00 |
| Mar 31, 2021 | 71,165.00 |